# Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection

> **NCT02073656** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 335 (actual)

## Conditions studied

- Hepatitis C Virus
- HIV

## Interventions

- **DRUG:** LDV/SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02073656
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-11
- **Final completion:** 2015-12
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073656, "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02073656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*